News | March 10, 2026
Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
The Silver Medal recognizes strong performance across sustainability, ethics, environment, labour & human rights, and responsible procurement
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
The decision marks a pivotal moment for the Massachusetts-based biotech giant
During live demonstrations, industry leaders highlighted SEOPRO’s ability to spot portfolio risk, execution bottlenecks, and decision delays early—before they escalate into costly program disruptions
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Subscribe To Our Newsletter & Stay Updated
